Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Published:2018-07 Issue:10143 Volume:392 Page:222-231
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Wallace Daniel J,Furie Richard A,Tanaka Yoshiya,Kalunian Kenneth C,Mosca Marta,Petri Michelle A,Dörner Thomas,Cardiel Mario H,Bruce Ian N,Gomez Elisa,Carmack Tara,DeLozier Amy M,Janes Jonathan M,Linnik Matthew D,de Bono Stephanie,Silk Maria E,Hoffman Robert W

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. New insights into the immunopathogenesis of systemic lupus erythematosus;Tsokos;Nat Rev Rheumatol,2016

2. Immunopathogenic mechanisms of systemic autoimmune disease;Wahren-Herlenius;Lancet,2013

3. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases;Schwartz;Nat Rev Drug Discov,2017

4. Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab;Hoffman;Arthritis Rheumatol,2017

5. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050;Fridman;J Immunol,2010

Cited by 403 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single gene defects and autoinflammation;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Clinical markers, metrics, indices, and clinical trials;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Cytokines in lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025

5. Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study;Clinical Rheumatology;2024-08-13